Definitive Contract 75N93020C00010
Award Date
6/1/20
Potential Completion Date
5/31/22
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Molecular Express, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
CRYSTAL CITY, CA 90220, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,993, was awarded to Molecular Express Inc. to develop a Vesivax platform-based liposomal formulation that will efficiently display the HIV immunogen. The solicitation sought proposals to conduct research and development in support of NIH and CDC agency missions, including alternatives to cell culture materials, cancer immunotherapy manufacturing, and...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Molecular Express, Inc., a minority-owned small business. The $296,286 fixed-price contract is for the development of self-replicating HIV vaccines using in vitro reconstituted virus-like particles. Molecular Express has previously worked on other infectious disease treatment and vaccine...
This is a $599,983 firm fixed-price contract awarded by the Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases to Molecular Express, Inc., a minority-owned small business, under the Small Business Innovation Research (SBIR) program. The objective of the contract is to develop an effective HIV vaccine by exploring co-delivery formulations of HIV antigens and adjuvants. This contract is part of the agency's "Evaluation...
The prime contractor Molecular Express Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, the contractor will engineer novel HIV GP41 ectodomain antigens for incorporation into VESIVAX immunogenic formulations, in response to a solicitation seeking proposals aligned with NIH and CDC public health missions. This total small business...
This is a $1,999,866.00 Firm Fixed Price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Molecular Express, Inc. for the design and engineering of Vesivax HIV immunogen formulations. The contract is a Total Small Business set-aside as part of the Small Business Innovation Research (SBIR) Program Phase II. Molecular Express is a minority-owned, self-certified small disadvantaged business...
Molecular Express Inc. was awarded a $2.3 million definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to evaluate different co-delivery methods of a model HIV antigen using the Vesivax liposomal platform. This contract was awarded under a Small Business Innovation Research solicitation issued jointly by NIH and the Centers for Disease Control and Prevention seeking proposals aligned with agency missions through innovative solutions...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Neovaxsyn Inc., a minority-owned small disadvantaged business located in Ames, Iowa. The $300,000 firm-fixed-price contract supports the development of innovative HIV/AIDS vaccine technologies, including the use of nanoparticle delivery systems and strategies to induce broadly...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,000,000.00 Small Business Innovation Research (SBIR) Phase II contract to Neovaxsyn Inc., a minority-owned, small disadvantaged business, to develop a nanovaccine for eliciting broadly neutralizing antibodies against HIV-1. The contract is a firm fixed price definitive contract with a completion date of June 30, 2027. Neovaxsyn Inc. has previously received federal funding from NIAID and the National Institute of...